Neues beim Schlaganfall 2022–2023

Der Schlaganfall ist nach wie vor eine der wichtigsten Ursachen für Invalidität und Tod weltweit. Auch in den Jahren 2022–2023 gab es eine Vielzahl von neuen Erkenntnissen bezüglich Primär- und Sekundärprävention, Akuttherapie und Behandlung intrakranieller Blutungen sowie Sinus-/Venenthrombosen, von denen die wichtigsten in diesem Übersichtartikel zusammengefasst werden sollen.

• Literatur

• 1 Davidson KW, Barry MJ, Mangione CM. et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA 2022; 327: 1577-1584
• 2 Svendsen JH, Diederichsen SZ, Højberg S. et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 2021; 398: 1507-1516
• 3 Diener HC, Aisenberg J, Ansell J. et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017; 38: 860-868
• 4 Diener HC, Aisenberg J, Ansell J. et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J 2017; 38: 852-859
• 5 Huisman MV, Teutsch C, Lu S. et al. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry. Clin Res Cardiol 2022; 111: 548-559
• 6 Lip GYH, Kotalczyk A, Teutsch C. et al. Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry. Clin Res Cardiol 2022; 111: 560-573
• 7 Chen X, Wang L, Li H. et al. Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: An updated traditional and Bayesian network meta-analysis. Front Pharmacol 2022; 13: 1049283
• 8 Connolly SJ, Karthikeyan G, Ntsekhe M. et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med 2022; 387: 978-988
• 9 Piccini JP, Caso V, Connolly SJ. et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 2022; 399: 1383-1390
• 10 Keyhani S, Cheng EM, Hoggatt KJ. et al. Comparative Effectiveness of Carotid Endarterectomy vs Initial Medical Therapy in Patients With Asymptomatic Carotid Stenosis. JAMA Neurol 2020; 77: 1110-1121
• 11 Reiff T, Eckstein H-H, Mansmann U. et al. Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. Lancet Neurol 2022; 21: 877-888
• 12 ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015; 385: 617-628
• 13 van den Berg SA, Uniken Venema SM, Reinink H. et al. Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke (MR ASAP): an ambulance-based, multicentre, randomised, open-label, blinded endpoint, phase 3 trial. Lancet Neurol 2022; 21: 971-981
• 14 Thelengana A, Radhakrishnan DM, Prasad M. et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurol Belg 2019; 119: 359-367
• 15 Kvistad CE, Næss H, Helleberg BH. et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurology 2022; 21: 511-519
• 16 Adusumilli G, Pederson JM, Hardy N. et al. Mechanical thrombectomy in anterior vs. posterior circulation stroke: A systematic review and meta-analysis. Interv Neuroradiol 2022;
• 17 Jovin TG, Nogueira RG, Lansberg MG. et al. Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis. Lancet 2022; 399: 249-258
• 18 Pérez de la Ossa N, Abilleira S, Jovin TG. et al. Effect of Direct Transportation to Thrombectomy-Capable Center vs Local Stroke Center on Neurological Outcomes in Patients With Suspected Large-Vessel Occlusion Stroke in Nonurban Areas: The RACECAT Randomized Clinical Trial. JAMA 2022; 327: 1782-1794
• 19 LeCouffe NE, Kappelhof M, Treurniet KM. et al. A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. N Engl J Med 2021; 385: 1833-1844
• 20 Fischer U, Kaesmacher J, Strbian D. et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial. Lancet 2022; 400: 104-115
• 21 Mitchell PJ, Yan B, Churilov L. et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial. Lancet 2022; 400: 116-125
• 22 Turc G, Tsivgoulis G, Audebert HJ. et al. European Stroke Organisation (ESO)-European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion. J Neurointerv Surg 2022; 14: 209
• 23 Qiu Z, Li F, Sang H. et al. Effect of Intravenous Tirofiban vs Placebo Before Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The RESCUE BT Randomized Clinical Trial. JAMA 2022; 328: 543-553
• 24 Lang SH, Manning N, Armstrong N. et al. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis. Curr Med Res Opin 2012; 28: 351-370
• 25 van der Steen W, van de Graaf RA, Chalos V. et al. Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. Lancet 2022; 399: 1059-1069
• 26 Liu X, Dai Q, Ye R. et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol 2020; 19: 115-122
• 27 Langezaal LCM, van der Hoeven EJRJ, Mont’Alverne FJA. et al. Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion. N Engl J Med 2021; 384: 1910-1920
• 28 Tao C, Li R, Zhu Y. et al. Endovascular treatment for acute basilar artery occlusion: A multicenter randomized controlled trial (ATTENTION). Int J Stroke 2022;
• 29 Jovin TG, Li C, Wu L. et al. Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion. N Engl J Med 2022; 387: 1373-1384
• 30 Xu J, Chen X, Chen S. et al. Endovascular treatment for basilar artery occlusion: a meta-analysis. Stroke Vasc Neurol 2023; 8: 1-3
• 31 Renú A, Millán M, San Román L. et al. Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. JAMA 2022; 327: 826-835
• 32 Chen HS, Cui Y, Li XQ. et al. Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial. JAMA 2022; 328: 627-636
• 33 Shoamanesh A, Mundl H, Smith EE. et al. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400: 997-1007
• 34 Diener HC, Rothwell PM. Antithrombotic drugs in secondary stroke prevention: still some way to go. Lancet 2022; 400: 974-975
• 35 Hindricks G, Potpara T, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498
• 36 Steffel J, Verhamme P, Potpara TS. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20: 1231-1242
• 37 Oldgren J, Åsberg S, Hijazi Z. et al. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation 2022; 146: 1056-1066
• 38 Chimowitz MI, Lynn MJ, Derdeyn CP. et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011; 365: 993-1003
• 39 Zaidat OO, Fitzsimmons BF, Woodward BK. et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015; 313: 1240-1248
• 40 Hanley DF, Lane K, McBee N. et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017; 389: 603-611
• 41 Kuramatsu JB, Gerner ST, Ziai WC. et al. Association of intraventricular fibrinolysis with clinical outcomes in ICH: an individual participant data meta-analysis. Stroke 2022; 53: 2876-2886
• 42 Al-Shahi Salman R, Keerie C, Stephen J. et al. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol 2021; 20: 842-853
• 43 Schreuder F, van Nieuwenhuizen KM, Hofmeijer J. et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol 2021; 20: 907-916
• 44 Al-Shahi Salman R, Dennis MS, Sandercock PAG. et al. Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage: Extended Follow-up of the RESTART Randomized Clinical Trial. JAMA Neurol 2021; 78: 1179-1186
• 45 Ferro JM, Coutinho JM, Dentali F. et al. Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial. JAMA Neurol 2019; 76: 1457-1465
• 46 Yaghi S, Shu L, Bakradze E. et al. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022; 53: 728-738